“创新药故事”带飞股价翻倍！福元医药上半年营收净利双降，创新药仅1项临床在研

Group 1 - The company has been actively advancing research and development innovations, with 8 generic drug varieties passing consistency evaluation and obtaining 3 clinical approval notices, while also completing 11 generic drug applications [1] - The company's stock price reached a peak of 31.61 yuan per share as of the close on the 18th, reflecting a cumulative increase of 110% since the low point on April 9 [1] - The recent surge in stock price may be attributed to market enthusiasm for "innovative drug stories," although the company currently has only one product (FY101 injection) in clinical stages [2] Group 2 - As of the end of the reporting period, the company had obtained 209 domestic drug registration approvals and had 126 products included in the national medical insurance catalog, with 48 in Class A and 54 in the national essential drug list [2] - For the fiscal year 2024, the company achieved revenue of 3.446 billion yuan, a slight increase of 3.17% year-on-year, while the net profit after deducting non-recurring items was 460 million yuan, a slight decrease of 3.65% year-on-year [2] - The company's main revenue source comes from drug formulations, which accounted for 93.12% of total revenue, amounting to 3.209 billion yuan [2]